中国现代神经疾病杂志 ›› 2025, Vol. 25 ›› Issue (3): 161-164. doi: 10.3969/j.issn.1672-6731.2025.03.001

• 专论 • 上一篇    下一篇

2 2024年中国脑胶质瘤诊断与治疗发展与创新

杨学军*(), 师炜, 张恺   

  1. 102218 清华大学附属北京清华长庚医院神经外科
  • 收稿日期:2025-03-15 出版日期:2025-03-25 发布日期:2025-04-21
  • 通讯作者: 杨学军
  • 基金资助:
    国家自然科学基金资助项目(82373151); 北京市自然科学基金资助项目(7232228)

Diagnosis and treatment development and innovations of glioma in China 2024

Xue-jun YANG*(), Wei SHI, Kai ZHANG   

  1. Department of Neurosurgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218, China
  • Received:2025-03-15 Online:2025-03-25 Published:2025-04-21
  • Contact: Xue-jun YANG
  • Supported by:
    National Natural Science Foundation of China(82373151); Beijing Natural Science Foundation(7232228)

摘要:

2024年中国脑胶质瘤的临床诊疗与研究领域取得了显著进展,涵盖基础研究、诊断技术、手术技术、靶向治疗、免疫治疗及综合管理等多方面,展示了我国在基础研究成果转化为临床应用方面的创新能力,推动了胶质瘤治疗向精准化和智能化发展。重要成果包括各学术组织在胶质瘤研究和临床实践中发挥关键作用,尤其是国家神经疾病医学中心脑胶质瘤MDT专科联盟的成立,整合资源,促进多学科合作,推动知识共享和临床转化;用于具有PTPRZ1-MET融合基因胶质瘤的间质上皮转化因子抑制剂的新靶向治疗获批上市;人工智能在胶质瘤研究中的应用;快速术中分子诊断技术的进展及基于人工智能的影像学分析与规律间隔成簇短回文重复序列快速检测的结合,将为胶质瘤的精准诊疗带来革命性变革。

关键词: 神经胶质瘤, 精准医学, 人工智能, 综述

Abstract:

In 2024, significant advancements were made in the diagnosis, treatment, and research of glioma in China, reflecting a comprehensive innovation in basic research, diagnostic technologies, surgical techniques, targeted therapies, immunotherapies, and integrated management. This development showcases China's increasing capabilities in translating basic research into clinical applications, advancing the precision and intelligence of glioma care. Key achievements include the major academic organizations had played pivotal roles in glioma research and clinical practice. Notably, the establishment of the Glioma MDT Specialist Alliance under the National Center for Neurological Disorders had enhanced resource integration, promoted multidisciplinary collaboration, and accelerated knowledge sharing and clinical translation. The approval of mesenchymal - epithelial transition (MET) inhibitors for glioma harboring the PTPRZ1-MET fusion gene marked a milestone in precision oncology. Artificial intelligence (AI) has been widely adopted in glioma research. Breakthroughs in rapid intraoperative molecular diagnostics, combined with AI-powered imaging analysis and clustered regularly interspaced short palindromic repeats (CRISPR), were poised to revolutionize precision diagnosis and treatment. These developments underscore China's growing leadership in integrating cutting-edge technologies to address complex challenges in neuro-oncology.

Key words: Glioma, Precision medicine, Artificial intelligence, Review